Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 6Phase 1/2 3Phase NA 1Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 4Glioma 3Brain Neoplasms 3Neoplasms, Basal Cell 1Mouth Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Leukoplakia 1Erythroplasia 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Aminolevulinic Acid × Clear all
NCT01128218 2023-11-30

A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors

Southern Illinois University

Phase 1/2 Completed
33 enrolled 15 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT00977795 2019-09-10

A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors

Endeavor Health

Phase 1/2 Withdrawn
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT02755142 2016-05-23

Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas

medac GmbH

Phase 1/2 Completed
21 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡